Central American Health Secretaries, Drug Companies Reach Agreement to Lower Cost of AIDS Drugs
January 30, 2003
Five major pharmaceutical companies reached an agreement with Central American health secretaries to reduce the cost of AIDS drugs for the region by up to 55 percent -- from between $2,500 and $2,800 to between $1,035 and $1,453. Under the accord, GlaxoSmithKline, Bristol-Myers Squibb, Merck Sharp and Dohme, P. Hoffman-La Roche and Boehringer Ingelheim agreed to lower the price of triple combination therapy drugs, the health officials announced in a joint statement. The agreement "is a milestone in the history of the AIDS epidemic, both in Central America and in a global context," said the statement, signed by health secretaries from Costa Rica, Guatemala, Honduras, El Salvador, Nicaragua and Panama. The secretaries also promised that their governments would formulate plans to provide complete care to AIDS patients. There are 25,000 AIDS cases in Central America, and more than 180,000 Central Americans are HIV-positive, health officials estimate.Adapted from:
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.